open access
Polski
Endocrine implications of obesity and bariatric surgery


- Siemianowice Śląskie Municipal Hospital, Department of General Surgery,, 1 Maja 9 Street, Siemianowice Śląskie, Poland
- Center in Excellence in Poultry Science, University of Arkansas, Fayetteville,, Fayetteville, Arkansas, United States
- Josef Babinski Clinical Hospital in Kraków, Mehoffera 10, Krakow, Poland
- Josef Babinski Clinical Hospital in Kraków, Mehoffera 10, Krakow, Poland
- Department of Animal Physiology and Endocrinology, University of Agriculture in Krakow, Krakow, Poland
open access
Abstract
Abstract
Keywords
obesity; endocrine dysfunctions; bariatric surgery; gastrointestinal hormones


Title
Endocrine implications of obesity and bariatric surgery
Journal
Issue
Article type
Review paper
Pages
574-597
Published online
2018-09-12
Page views
4326
Article views/downloads
2945
DOI
10.5603/EP.2018.0059
Pubmed
Bibliographic record
Endokrynol Pol 2018;69(5):574-597.
Keywords
obesity
endocrine dysfunctions
bariatric surgery
gastrointestinal hormones
Authors
Michał Dyaczyński
Colin Guy Scanes
Helena Koziec
Helena Koziec
Krystyna Pierzchała-Koziec


- Friedman JM. Obesity in the new millennium. Nature. 2000; 404(6778): 632–634.
- Dhillo WS. Appetite regulation: an overview. Thyroid. 2007; 17(5): 433–445.
- de Lima-Júnior JC, Velloso LA, Geloneze B. The Obese Brain--Effects of Bariatric Surgery on Energy Balance Neurocircuitry. Curr Atheroscler Rep. 2015; 17(10): 57.
- World Health Organization. Report of a WHO Consultation. Obesity: preventing and managing the global epidemic Geneva, Switzerland WHO, 2000.
- World Health Organisation. Ten facts on obesity 2013 (5/9/2013). http://www.who.int/features/factfiles/obesity/en/index.html.
- Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev. 2007; 29: 1–5.
- Kozakowski J, Lebovitz HE, Zgliczyński W, et al. Gastric Contractility Modulation - a novel method for the treatment of type 2 diabetes mellitus and obesity. Endokrynol Pol. 2017; 68(5): 579–584.
- Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007; 335(7631): 1194–1199.
- Rodgers S, Burnet R, Goss A, et al. Jaw wiring in treatment of obesity. Lancet. 1977; 1(8024): 1221–1222.
- Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg. 2009; 19(12): 1605–1611.
- Beck B. Neuropeptides and obesity. Nutrition. 2000; 16(10): 916–923.
- Steele CA, Cuthbertson DJ, MacFarlane IA, et al. Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. Eur J Endocrinol. 2013; 168(4): 501–507.
- Menyhért J, Wittmann G, Hrabovszky E, et al. Interconnection between orexigenic neuropeptide Y- and anorexigenic alpha-melanocyte stimulating hormone-synthesizing neuronal systems of the human hypothalamus. Brain Res. 2006; 1076(1): 101–105.
- Williams KW, Elmquist JK. Lighting up the hypothalamus: coordinated control of feeding behavior. Nat Neurosci. 2011; 14(3): 277–278.
- Zhan C, Zhou J, Feng Q, et al. Acute and long-term suppression of feeding behavior by POMC neurons in the brainstem and hypothalamus, respectively. J Neurosci. 2013; 33(8): 3624–3632.
- Lei L, Gu Y, Murphy JG, et al. Brainstem raphe pallidus and the adjacent area contain a novel action site in the melanocortin circuitry regulating energy balance. Life Sci J. 2008; 5(3): 1–13.
- Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest. 2007; 117(1): 13–23.
- Bloomgarden ZT. Gut and adipocyte peptides. Diabetes Care. 2006; 29(2): 450–456.
- Ockander L, Hedenbro JL, Rehfeld JF, et al. Jejunoileal bypass changes the duodenal cholecystokinin and somatostatin cell density. Obes Surg. 2003; 13(4): 584–590.
- Matson CA, Reid DF, Cannon TA, et al. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol. 2000; 278(4): R882–R890.
- Whitmore TE, Holloway JL, Lofton-Day CE, et al. Human secretin (SCT): gene structure, chromosome location, and distribution of mRNA. Cytogenet Cell Genet. 2000; 90(1-2): 47–52.
- Baldwin GS, Patel O, Shulkes A. Evolution of gastrointestinal hormones: the cholecystokinin/gastrin family. Curr Opin Endocrinol Diabetes Obes. 2010; 17(1): 77–88.
- Sanger GJ, Wang Y, Hobson A, et al. Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol. 2013; 170(7): 1323–1332.
- Lang R, Gundlach AL, Holmes FE, et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev. 2015; 67(1): 118–175.
- Amato A, Baldassano S, Mulè F. GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity. J Endocrinol. 2016; 229(2): R57–R66.
- Nauck M, Schmidt WE, Ebert R, et al. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab. 1989; 69(3): 654–662.
- Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 2014; 16(8): 673–688.
- Vidal J, de Hollanda A, Jiménez A. GLP-1 is not the key mediator of the health benefits of metabolic surgery. Surg Obes Relat Dis. 2016; 12(6): 1225–1229.
- Gourcerol G, St-Pierre DH, Taché Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Regul Pept. 2007; 141(1-3): 1–7.
- le Roux CW, Batterham RL, Aylwin SJB, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2006; 147(1): 3–8.
- Laferrère B, Swerdlow N, Bawa B, et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010; 95(8): 4072–4076.
- Willesen MG, Kristensen P, Rømer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology. 1999; 70(5): 306–316.
- Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402(6762): 656–660.
- Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000; 141(11): 4255–4261.
- Pournaras DJ, le Roux CW. Ghrelin and metabolic surgery. Int J Pept. 2010; 2010.
- Dickson SL, Egecioglu E, Landgren S, et al. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol. 2011; 340(1): 80–87.
- Benarroch EE. Endogenous opioid systems: current concepts and clinical correlations. Neurology. 2012; 79(8): 807–814.
- Gosnell BA, Levine AS. Reward systems and food intake: role of opioids. Int J Obes (Lond). 2009; 33 Suppl 2: S54–S58.
- Davis CA, Levitan RD, Reid C, et al. Dopamine for. Obesity (Silver Spring). 2009; 17(6): 1220–1225.
- Guillemin R. Somatostatin: the beginnings, 1972. Mol Cell Endocrinol. 2008; 286(1-2): 3–4.
- Rigamonti AE, Cella SG, Bonomo SM, et al. Effect of somatostatin infusion on peptide YY secretion: studies in the acute and recovery phase of anorexia nervosa and in obesity. Eur J Endocrinol. 2011; 165(3): 421–427.
- Martinez V. Somatostatin. Handbook of Biologically Active Peptides. 2013: 1320–1329.
- Ando H. Somatostatin. Handbook of Hormones. 2016: 36-e5–4.
- Ottaviani E, Malagoli D, Franceschi C. The evolution of the adipose tissue: a neglected enigma. Gen Comp Endocrinol. 2011; 174(1): 1–4.
- Bilir BE, Güldiken S, Tunçbilek N, et al. The effects of fat distribution and some adipokines on insulin resistance. Endokrynol Pol. 2016; 67(3): 277–282.
- García-Solís P, García OP, Hernández-Puga G, et al. Thyroid hormones and obesity: a known but poorly understood relationship. Endokrynol Pol. 2018; 69(3): 292–303.
- Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, et al. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J). 2007; 83(5 Suppl): S192–S203.
- Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines--energy regulation from the human perspective. J Nutr. 2006; 136(7 Suppl): 1935S–1939S.
- Krysiak R, Żmuda W, Marek B, et al. Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels. Endokrynol Pol. 2016; 67(3): 271–276.
- Baranowska-Bik A, Baranowska B, Martyńska L, et al. Adipokine profile in patients with anorexia nervosa. Endokrynol Pol. 2017; 68(4): 422–429.
- Sirbu AE, Buburuzan L, Kevorkian S, et al. Adiponectin expression in visceral adiposity is an important determinant of insulin resistance in morbid obesity. Endokrynol Pol. 2018; 69(3): 252–258.
- Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998; 395(6704): 763–770.
- Khan SM, Hamnvik OPR, Brinkoetter M, et al. Leptin as a modulator of neuroendocrine function in humans. Yonsei Med J. 2012; 53(4): 671–679.
- Hwa JJ, Fawzi AB, Graziano MP, et al. Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice. Am J Physiol. 1997; 272(4 Pt 2): R1204–R1209.
- Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002; 13(1): 18–23.
- Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307–312.
- Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004; 89(6): 2563–2568.
- Wojciechowska C, Jacheć W, Romuk E, et al. The effect of BMI, serum leptin, and adiponectin levels on prognosis in patients with non-ischaemic dilated cardiomyopathy. Endokrynol Pol. 2017; 68(1): 26–34.
- Matsuzawa Y. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl. 2005; 6(2): 7–14.
- Siemińska L, Borowski A, Marek B, et al. Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia. Endokrynol Pol. 2018; 69(2): 120–127.
- Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26(3): 439–451.
- Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307(5708): 426–430.
- Davutoglu M, Ozkaya M, Guler E, et al. Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly. 2009; 139(1-2): 22–27.
- Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 2011; 12: 60.
- Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine. 2012; 41(2): 176–182.
- Tham JCh, leRoux CW. Benefits of bariatric surgery and perioperative surgical safety. EMJ Diabet. 2015; 3: 66–71.
- Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009(2): CD003641.
- Lucchese M, Scopinaro N. Metabolic surgery. In: Buchwald H. ed. Minimally invasive bariatric and metabolic surgery: principles and technical aspects. Springer 2015: 69–79.
- Buchwald H. Overview of bariatric surgery. J Am Coll Surg. 2002; 194(3): 367–375.
- Moshiri M, Osman S, Robinson TJ, et al. Evolution of bariatric surgery: a historical perspective. AJR Am J Roentgenol. 2013; 201(1): W40–W48.
- Chang SH, Stoll CRT, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014; 149(3): 275–287.
- Melissas J. The bariatric multidisciplinary center.Lucchese M, Scopinaro N. ed. Minimally invasive bariatric and metabolic surgery: principles and technical aspects 2015: 59–67.
- le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007; 246(5): 780–785.
- Demirpence M, Yilmaz H, Colak A, et al. The effect of sleeve gastrectomy on serum irisin levels in patients with morbid obesity. Endokrynol Pol. 2016; 67(5): 481–486.
- Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93(7): 2479–2485.
- Chan JL, Mun EC, Stoyneva V, et al. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring). 2006; 14(2): 194–198.
- Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010; 110(4): 571–584.
- Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002; 346(21): 1623–1630.
- Reinehr T, Roth CL, Schernthaner GH, et al. Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically induced weight loss. Obes Surg. 2007; 17(12): 1571–1577.
- Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol. 2007; 58 Suppl 1: 13–35.
- Christou NV, Look D, McLean AP. Pre- and post-prandial plasma ghrelin levels do not correlate with satiety or failure to achieve a successful outcome after Roux-en-Y gastric bypass. Obes Surg. 2005; 15(7): 1017–1023.
- Gonzalez-Campoy JM, Richardson B, Richardson C, et al. Bariatric endocrinology: principles of medical practice. Int J Endocrinol. 2014; 2014: 917813.
- Lutz TA, Bueter M. The Use of Rat and Mouse Models in Bariatric Surgery Experiments. Front Nutr. 2016; 3: 25.
- Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond). 2013; 37(11): 1452–1459.
- Pierzchała-Koziec K, Scanes CG, Zubel-łojek J, et al. Met-enkephalin-like peptides and ghrelin mitigate negative effects of bariatric surgery in rats. Acta Biol Cracovien ser Zool. 2014; 55/56: 100–107.
- Clements RH, Gonzalez QH, Long CI, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg. 2004; 70(1): 1–4; discussion 4.
- Fernández-Soto ML, Martín-Leyva A, González-Jiménez A, et al. Remission of type 2 diabetes mellitus after bariatric surgery - comparison between procedures. Endokrynol Pol. 2017; 68(1): 18–25.
- Meek CL, Lewis HB, Reimann F, et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides. 2016; 77: 28–37.
- Ochner CN, Gibson C, Shanik M, et al. Changes in neurohormonal gut peptides following bariatric surgery. Int J Obes (Lond). 2011; 35(2): 153–166.